Data-Gouv-ML/pcri-informations-sur-les-projets-laureats huggingface dataset:
Transparent Solar Panel Technology for Energy Autonomous Greenhouses (PanePowerSW)

Framework: Horizon 2020 — Societal Challenges
Action type: SME instrument
Countries involved: Greece
Call: H2020-EIC Accelerator pilot –SME Instrument - Green Deal (H2020-EIC-SMEInst-2018-2020-4, 2020)
Start date: 2020-12-01
End date: 2023-03-31
Duration (months): 28.0
Total project cost (EUR): 1310273.75
EU funding (EUR): 917191.63
Participants: 1
Project status: CLOSED

According to United Nations, the world population will reach 9.7 billion by 2050. Food, energy and water are three critical resources that must be managed for mankind to thrive. With these figures, a 70-100% increase in food supply will be needed to maintain our current nutrition levels. Given that agriculture accounts for 14% of world’s energy usage, 70% of water usage and 11% of CO2 emissions, it is clear that new technology is needed for feeding the world in a sustainable way. Greenhouse farming is as it increases the food production per m2 up to 10x compared to open field agriculture, while using 10x less water. However, Greenhouses require 10x the energy to operate. This is the market opportunity driving our technology development Brite has developed PanePower Solar Window (SW) which is a unique transparent (80%) solar glass panel that generates clean energy. The solar glass combines a nanostructured coating material with silicon solar cell technology to deliver a product ideally suited for greenhouse applications. PanePowerSW contributes in reducing the energy operating costs in greenhouses from 25-28% (of their total operating cost) to near zero depending on climate conditions. The technology enables the growth of almost any kind of crop because it is uniformly transparent over the visible spectrum. Our company has won grants from SME Instrument (Phase 1 and Phase 2), which enabled the technology of PanePowerSW to reach a TRL of 7. By applying to the EIC Accelerator Complementary Blended Finance program, we expect to enter the market in 2021, and sell at least 4 million m2 of solar glass (equivalent to over €160 M of cumulative revenue) by 2026. At our exit (within 5-6 years) we project a return on investment for the EIC equity funding of 7x or higher.

Keywords: sustainable agriculture,solar glass,transparency,nanomaterial coating
PRECEDE: PancREatic Cancer Early DEtection (PRECEDE)

Framework: Horizon 2020 — Societal Challenges
Programme: Health, demographic change and wellbeing
Theme: Treating and managing disease
Action type: SME instrument
Countries involved: United Kingdom
Call: Clinical research for the validation of biomarkers and/or diagnostic medical devices (H2020-SMEINST-1-2014, 2014)
Start date: 2014-10-01
End date: 2015-03-31
Duration (months): 6.0
Total project cost (EUR): 71429.0
EU funding (EUR): 50000.0
Participants: 1
Project status: CLOSED

PRECEDE (PancREatic Cancer Early DEtection): Pancreatic cancer is a devastating disease. Five year survival is only 3% and this figure has not changed for 40 years. A recent EU study has shown that this is the only cancer who’s incidence and mortality are set to increase. By the time patients present with symptoms, the disease is usually advanced and untreatable. The most effective way to improve survival would be to diagnose the disease earlier when therapy is more likely to be successful. CA19.9 is an approved biomarker for aiding diagnosis of pancreatic cancer in symptomatic individuals. Its sensitivity and specificity are not high enough for screening healthy high risk individuals due to the high number of false positives caused by the natural variation in levels within a population. Abcodia has developed an algorithm that learns an individual’s healthy baseline of CA19.9 and spots any inflection point as pancreatic cancer develops. This personalisation of the CA19.9 test increases sensitivity by identifying low but increasing values, improves specificity by discounting high but flat profiles and detects the disease earlier through regular testing and spotting inflection points. Abcodia has developed the algorithm based on longitudinal pre-diagnosis levels of CA19.9 levels from 64 pancreatic cancer cases and 161 healthy controls from the UK Collaborative Trial in Ovarian Cancer Screening, which for over 10 years monitored the health of 202,000 initially free from cancer women. The algorithm improves the performance of the marker CA19.9 and detects the disease earlier than standard diagnostic practice. The algorithm now requires clinical validation in a population based clinical trial across Europe to allow full commercialisation. This phase 1 project will build a robust business plan for the validation and commercialisation of one of the first examples of a personalised screening diagnostic that aims to finally improve survival in this devastating disease.

Keywords: pancreatic cancer,cancer screening,early diagnosis,ca19 9,longitudinal algorithm
Securing future-proof environmentally compatible bioenergy chains (SECURECHAIN)

Framework: Horizon 2020 — Societal Challenges
Programme: Secure, clean and efficient energy
Theme: Low-cost, low-carbon energy supply
Action type: Coordination and support actions
Countries involved: Estonia,Austria,Spain,Germany,Spain,Germany,Greece,Greece,Sweden,Netherlands,United Kingdom
Call: Market uptake of existing and emerging sustainable bioenergy (H2020-LCE-2014-3, 2014)
Start date: 2015-04-01
End date: 2018-07-31
Duration (months): 40.0
Total project cost (EUR): 1809586.25
EU funding (EUR): 1809586.25
Participants: 11
Project status: CLOSED

SecureChain promotes a Sustainable Supply Chain Management (SSCM) that meets highest environmental quality standards and targets local biomass suppliers, energy producers and financial sector players to mobilise more biomass, maximise the share of sustainable bioenergy in the final energy consumption, and reduce the transaction costs for further market uptake of most efficient systems in six European model regions. An open call for SSCM pilot projects is launched encouraging market actors to mobilise and secure additional supplies of biomass from regional sources. Following a merit-based, objective competition, selected SMEs are awarded 15-20 Innovation Vouchers for the realisation of proposed SSCM pilot projects with the support of specialised advisors. Learning Labs for SME clusters support the implementation of most sustainable and energy efficient solutions in each model region. Tested quality assurance tools are readily installed in the pilots and SMEs receive proper training. A complete LCA of pilot supply chains evaluates their broader environmental and socio-economic impacts, ensuring that QA protocols meet eligible international sustainability standards for high efficiency and low carbon footprint. Suppliers are prepared for and ultimately acquire sustainability certification via independent audits. To facilitate critical financial proofs for market actors and financiers, a risk assessment of supply chains in line with a close mentoring of pilot teams by financial advisors is carried out. Roadshows promoting the pilots showcase that future-proof investment proposals can attract local to international capital for secured implementation and upscaling of efficient solutions. SecureChain exploits and disseminates a broadly transferable SSCM model for local bioenergy chains that fosters sustainable, environmentally compatible mobilisation of biomass sources and a proactive promotion of the market through conscious investments into the bioenergy sector.

Keywords: biomass mobilisation,environmental impact assessment,supply chain management,quality assurance,capacity building,risk assesment,certification,regional initiatives,clusters
High Fidelity Electric Modelling and Testing (HiFi-ELEMENTS)

Framework: Horizon 2020 — Societal Challenges
Programme: Smart, green and integrated transport
Action type: Research and Innovation actions
Partnership: EGVI (cPPP)
Countries involved: Germany,Spain,Austria,Germany,Germany,Germany,Spain,Italy,Italy,Belgium,Türkiye,France,Czechia,Netherlands,United Kingdom,United Kingdom
Call: Multi-level modelling and testing of electric vehicles and their components (H2020-GV-2017, 2017)
Start date: 2017-10-01
End date: 2020-12-31
Duration (months): 39.0
Total project cost (EUR): 7532318.75
EU funding (EUR): 7532318.75
Participants: 19
Project status: CLOSED

Within the automotive product development cycle virtual and heterogeneous testing is becoming increasingly established through component, module and vehicle-level simulation and Hardware-in-the-Loop test-beds—enabled by ever increasing computing power and communications bandwidth available. Though a number of standards in this field have been established (FMI, ASAM XiL API), models are still mostly created in a fragmented manner: using domain-specific tools to create, manage and execute simulations; no standardisation of the content of the functional interfaces (FMI does standardise the format); limited scalability. This fragmentation leads to a lot of redundant effort as models of the same component or system are re-created several times. HiFi-ELEMENTS will address this fragmentation through two main mechanisms: Firstly, we will develop, validate and publish a recommendation for standardisation of model interfaces for common e-drive components (e-machine, inverter, battery, DC/DC converter, thermal management system), and will implement compliant versions of existing models. Secondly, we will implement a seamless workflow linking extended versions of existing tools—a model/data management tool and a co-simulation tool for MiL and HiL environments—augmented with effort-saving automated methods for model parameterisation and test case generation. Validation of standardised models and workflow will be done in 4 industrially relevant use cases depicting 4 common scenarios in e-drivetrain and EV development. On project conclusion, the interface recommendations and workflow methods will be disseminated in order to gain widespread EV-industry adoption. Consortium partners are very intensive users of virtual testing and will directly use the project results, while tool vendor partners will exploit the results by bringing extended software tools to market.

Keywords: modelling,simulation,co optimisation,standardisation
Electrochemically-enabled high-throughput peptidomics for next-generation precision medicine (ElectroMed)

Framework: Horizon 2020 — Excellent Science
Programme: Future and Emerging Technologies (FET)
Theme: EIC Pathfinder
Destination: Novel ideas for radically new technologies
Action type: Research and Innovation actions
Countries involved: Spain,France,Netherlands,Denmark,United Kingdom,Luxembourg
Call: FET-Open Challenging Current Thinking (H2020-FETOPEN-2018-2019-2020-01, 2019)
Start date: 2020-01-01
End date: 2023-12-31
Duration (months): 48.0
Total project cost (EUR): 2999167.5
EU funding (EUR): 2999167.5
Participants: 6
Project status: SIGNED

The uptake of proteomics for precision or personalised medicine applications requires the development of an effective screening instrument capable of detecting proteins at the low concentrations they are found in biological conditions while addressing their large chemical variability. The ElectroMed project's objective is to build and validate a proof-of-concept prototype of a programmable high-throughput peptide microarray technology. It is based on the radical vision of integrating electrochemical synthesis of peptide bioreceptors to enable programmable in situ protein detection with nano-functionalised FinFET sensors for high-performance data acquisition within a microfluidic-driven multiplexed platform for parallel screening. The project will undertake the research and innovation work required to 1) demonstrate multiplexed electrochemical peptide synthesis (EPS), 2) develop new FinFET sensors and 3) integrate EPS and the FinFET sensors in a single cost-effective prototype that we will validate in laboratory-relevant conditions. The ElectroMed project will achieve a technology breakthrough of the first fully-programmable in situ protein screening instrument. This prototype small-size single instrument will come as a faster, cheaper, and more efficient technology than current protein screening instruments. The potential impact is to significantly ease and reduce the price of protein screening to trigger an uptake of protein detection in healthcare (our primary focus) as well as in the food sector (food authenticity and traceability, allergens, GMOs or toxins detection all along food the value chain), environmental remediation or defense (detection of biological warfare agents). Electromed has also engaged to investigate COVID19 related peptide biomarkers and technology for the diagnosis of the infection and the relevant peptide protein iterations.

Keywords: protein binding,electrochemical synthesis,field effect transistor,microfluidics,precision medicine,personalised medicine,biomarker,multiplexing,microarray,sensor
Vaginal Arco-ColpoSuspension Device for the treatment of Urinary Incontinence in Women (VACS-D)

Framework: Horizon 2020 — Industrial Leadership
Programme: Innovation in SMEs
Action type: SME instrument
Countries involved: Türkiye
Call: SME instrument (H2020-EIC-SMEInst-2018-2020-3, 2020)
Start date: 2020-06-15
End date: 2022-06-14
Duration (months): 24.0
Total project cost (EUR): 976250.0
EU funding (EUR): 683375.0
Participants: 1
Project status: CLOSED

Stress Urinary Incontinence (SUI), referring to the involuntary leakage of urine, is a disease that causes embarrassment to sufferers that can lead to isolation, depression, and limitations in working and social life, especially exercise and leisure activities. Our VACS-D will disrupt existing applications for treatment by not only lowering the costs of healthcare making it more accessible by a larger population but also provide a pain free and long lasting solution that will also increase the quality of life as the world population age increases. VACS-D helps a major part of population – women- anywhere in the world. The women’s health is NOT just important for themselves but also from the sustained quality of motherhood as they raise the next generation. This is a new device with a patent pending (PCT/tr2019/050048) device for the treatment of SUI in women with the power of changing their lives for the better as they age. VACS-D preserves the advantages while eliminating the disadvantages of two surgical methods that were considered the optimum approach in 1965 and 2000. The device enables surgeons to perform surgery via the vagina in a minimally invasive way, with only a single incision and with no need for an artificial implant (mesh), relying instead on native tissue repair. The use of mesh was suspended in the UK in 2018 and in the USA after the reports of FDA in 2008 advising against their use. VACS-D facilitates a new surgical approach that will become the method of choice in the treatment of urinary incontinence in women. Our multidisciplinary team has extensive clinical and surgical experience in both abdominal colposuspension and midurethral sling operations approaches to the surgical treatment of urinary incontinence. In 2018, the founder, gynecologist and obstetrician Assoc. Prof. Dr. Özgür Yeniel formed a multidisciplinary team after recognizing the need for a new surgical approach.

Keywords: urinary incontinence
Mechanisms of human DNA replication (Human Repl Mech)

Framework: Horizon 2020 — Excellent Science
Programme: Marie-Sklodowska-Curie Actions
Theme: Marie Skłodowska-Curie
Destination: Individual Fellowships (IF)-Standard European Fellowships
Action type: Marie Skłodowska-Curie actions
Panel: Life Sciences
Countries involved: United Kingdom
Call: Individual Fellowships (H2020-MSCA-IF-2018, 2018)
Start date: 2019-04-01
End date: 2021-03-31
Duration (months): 24.0
Total project cost (EUR): 212933.76
EU funding (EUR): 212933.76
Participants: 1
Project status: CLOSED

Eukaryotic DNA replication is mediated by a complex machinery consisting of several dozen proteins that ensures precise duplication of chromosomes in S phase of the cell cycle. The Diffley laboratory recently reconstituted the core Saccharomyces cerevisiae replication machinery in vitro from 19 replication factors containing about 50 individual protein subunits. This system allowed to study mechanisms of yeast MCM loading onto DNA and of yeast CMG replicative helicase activation. In human cells however, the process of replication initiation and its regulation are less well understood. In particular, the firing factors that activate the CMG helicase differ in domain composition and phospho-regulation from the yeast orthologs. Mechanistic studies are required to understand how human DNA replication is initiated and regulated at the molecular level. I will first reconstitute human DNA replication in vitro from completely recombinant components using methodology that I developed during my PhD. I will then use this system to study how the human replicative helicase is activated on the molecular level and how activation is regulated by phosphorylation using biochemistry. I will use cryo-electron microscopy (cryo-EM) to study the architecture of complexes involved in replication initiation. The reconstituted human system could in future enable studies on disease mechanisms and could allow screening for antiproliferative small molecule inhibitors.

Keywords: dna replication,in vitro reconstitution,human proteins,cmg helicase activation,regulation,phosphorylation,biochemistry,cryo em,protein complexes,baculovirus insect cell expression,bigbac
Patient Preferences in benefit risk assessments during the drug life cycle - Sofia ref.: 115966 (PREFER)

Framework: Horizon 2020 — Societal Challenges
Programme: Health, demographic change and wellbeing
Theme: Public-private partnerships
Destination: Innovative Medicines Initiative 2
Action type: Research and Innovation actions
Partnership: IMI2 (Art-187)
Countries involved: Germany,Germany,Germany,Germany,Germany,Italy,Italy,Germany,Belgium,Belgium,Belgium,Switzerland,Switzerland,Switzerland,Belgium,Sweden,Sweden,France,Netherlands,Netherlands,Netherlands,United States,United Kingdom,United Kingdom,United Kingdom,United Kingdom,United Kingdom,United Kingdom,United Kingdom,United Kingdom,United Kingdom
Call: Patient perspective elicitation on benefits and risks of medicinal products, from development through the entire life cycle, to inform the decision-making process by regulators and Health Technology Assessment bodie (H2020-JTI-IMI2-2015-05-two-stage, 2015)
Start date: 2016-10-01
End date: 2022-05-31
Duration (months): 68.0
Total project cost (EUR): 12015547.51
EU funding (EUR): 6000000.0
Participants: 37
Project status: CLOSED

The PREFER project will deliver an overview and evaluation of preference elicitation methods to be applied in the entire drug life cycle, i.e. in the early stages of identifying medical needs, in clinical testing, to guide decisions on reimbursement and to make decisions on withdrawal of drugs from the market. A broad array of (combinations of) patient preference methods will be tested prospectively in a large number of case studies. The availability of large patient cohorts will enable to test new methods or deviations from existing methods in a randomized manner, by comparing well-known methods with newer ones. The use of simulation studies will both contribute to smarter design of case studies and to exploring the sensitivity of outcomes of preference studies. Based on discussions with a broad representation of stakeholders e.g. patients, patient organisations, regulatory authorities, HTA bodies and reimbursement agencies, suitable methods will be tested and their contributions to improved decision making will be discussed in recommendations adapted to the needs of all relevant stakeholders. The recommendations from PREFER are expected to lead to changed practices, in that industry will routinely assess whether a preference study would add value at key decision points in the medicinal product life cycle and, if so, implement patient-preference elicitation studies according to the PREFER project recommendations. The PREFER consortium consist of 16 industry partners and 16 academic and SME members including representation from academia, patient organizations, HTA bodies, reimbursement agencies, and project management.

Keywords: patient preferences,conjoint analysis,reumatoid arthritis,neuromuscular disorders,lung cancer,ethics,recommendations,drug development
Southern Ocean and Antarctic Climatic Phasing:Tephrochronological Correlation of Southern Ocean Marine Records and Antarctic Ice-cores (SHARP)

Framework: Horizon 2020 — Excellent Science
Programme: Marie-Sklodowska-Curie Actions
Theme: Marie Skłodowska-Curie
Destination: Individual Fellowships (IF)-Global Fellowships
Action type: Marie Skłodowska-Curie actions
Panel: Environment and Geosciences
Countries involved: Switzerland,United Kingdom
Call: Marie Skłodowska-Curie Individual Fellowships (IF-GF) (H2020-MSCA-IF-2014, 2014)
Start date: 2016-09-01
End date: 2019-08-31
Duration (months): 36.0
Total project cost (EUR): 267147.0
EU funding (EUR): 267147.0
Participants: 2
Project status: CLOSED

Determining the temporal relationships of large-scale atmospheric and oceanic fluctuations is crucial for advancing understanding of the mechanisms controlling heat transfer between the Northern and Southern Hemispheres. The thermal bipolar see-saw caused asynchronous interhemispheric climatic changes during the last glacial period and Southern Ocean marine records and the Antarctic ice-cores are valuable archives recording this past climatic variability. Ascertaining the precise phasing of the climatic variability between these records provides crucial boundary conditions for testing models simulating the future behaviour of the bipolar see-saw and assessing potential large-scale oceanic and atmospheric reorganisations under anthropogenic forcing. In addition, establishing tighter constraints on phase relationships between sedimentary evidence for deep-water ventilation of CO2, and ice-core evidence for past atmospheric CO2 variations is key to determining the future response of the Earth system to rising CO2 levels. This project will address this challenge by ascertaining the rate, timing and phasing of Southern Hemisphere climatic changes between 40-10 kyr BP using tephrochronology to independently synchronise the palaeoclimatic sequences using common horizons of volcanic ash as time-synchronous tie-lines. Recognition of ash horizons not visible upon core inspection (cryptotephras) within sequences increasingly distal from volcanic regions has increased the scope of this technique. Cryptotephra identification methods will be used to trace ash horizons visible in Antarctic ice-cores into a marine core network from the Southern Ocean Atlantic sector and to trace previously unknown horizons identified in the marine realm into the Antarctic Atlantic sector EPICA DML ice-core. This region has a high potential for synchronisation due to the number of upwind volcanic regions that have previously deposited volcanic ash over the ice-sheet and Southern Ocean.

Keywords: tephrochronology,palaeoclimate reconstruction,southern ocean,bipolar see saw